XNAS
CAI
Market cap7.77bUSD
Oct 08, Last price
27.50USD
1D
1.48%
1Q
61.86%
IPO
0.92%
Name
Caris Life Sciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
74.32%
Rev. gr., 5y
14.28%
Revenues
812m
+96.97%
Net income
-538m
L+90.84%
CFO
83m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Key people
David Spetzler
President
Brian Brille
Vice Chairman of the Board, Executive Vice President · since 2018
Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer · since 2023
Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer · since 2023
George Poste
Vice Chairman of the Board
Independent Director · since 2024
Independent Director · since 2021
Jeffrey Vacirca
Independent Director · since 2024
Legal address
C/O C T CORPORATION SYSTEM
1999 BRYAN ST., STE. 900
DALLAS, TX 75201
US
1999 BRYAN ST., STE. 900
DALLAS, TX 75201
US
Headquarters
1999 BRYAN ST STE 900
Suite 800
DALLAS, TX 75201
US
Suite 800
DALLAS, TX 75201
US
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |